High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: study protocol for TBTC Study 31/ACTG A5349 phase 3 clinical trial

INTRODUCTION: Phase 2 clinical trials of tuberculosis treatment have shown that once-daily regimens in which rifampin is replaced by high dose rifapentine have potent antimicrobial activity that may be sufficient to shorten overall treatment duration. Herein we describe the design of an ongoing phas...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Contemp Clin Trials
Hoofdauteurs: Dorman, Susan E., Nahid, Payam, Kurbatova, Ekaterina V., Goldberg, Stefan V., Bozeman, Lorna, Burman, William J., Chang, Kwok-Chiu, Chen, Michael, Cotton, Mark, Dooley, Kelly E., Engle, Melissa, Feng, Pei-Jean, Fletcher, Courtney V., Ha, Phan, Heilig, Charles M., Johnson, John L., Lessem, Erica, Metchock, Beverly, Miro, Jose M., Nhung, Nguyen Viet, Pettit, April C., Phillips, Patrick P.J., Podany, Anthony T., Purfield, Anne E., Robergeau, Kathleen, Samaneka, Wadzanai, Scott, Nigel A., Sizemore, Erin, Vernon, Andrew, Weiner, Marc, Swindells, Susan, Chaisson, Richard E.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2020
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307310/
https://ncbi.nlm.nih.gov/pubmed/31981713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cct.2020.105938
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items